SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2021

Sep. 30, 2021

Jun. 30, 2021

Dec. 31, 2020

Schedule of reconciliation of common stocks reflected in the condensed balance sheets

	2020	2019
Preferred shares authorized
Series A preferred	6,746,233	6,746,233
Series B preferred	7,588,369	7,588,369
Series C preferred	6,001,269	6,001,269
Series D preferred	12,317,871	17,596,960
Series D1 preferred	9,038,488	—
Total preferred shares authorized	41,692,230	37,932,831

	2020	2019
Preferred shares issued and outstanding
Series A preferred	6,641,371	6,746,233
Series B preferred	7,588,369	7,588,369
Series C preferred	6,001,269	6,001,269
Series D preferred	12,317,871	12,317,871
Series D1 preferred	9,038,488	—
Total preferred shares issued and outstanding	41,587,368	32,653,742

Schedule of basic and diluted net income (loss) per common stock

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Numerator:
Net Loss	$	(14,691,871)	$	(7,683,830)	$	(29,232,518)	$	(19,349,948)
Denominator:
Basic weighted average common shares outstanding		4,551,755		8,522,923		3,818,717		8,458,434
Earnings (loss) per share:
Basic and diluted	$	(3.23)	$	(0.90)	$	(7.66)	$	(2.29)

	2020		2019
Numerator:
Net Loss	$	(31,674,084)	$	(18,468,776)
Denominator:
Basic weighted average common shares outstanding		8,197,409		8,310,333
Earnings (loss) per share:
Basic and diluted	$	(3.86)	$	(2.22)

LifeSci Acquisition II Corp

Schedule of reconciliation of common stocks reflected in the condensed balance sheets

At September 30, 2021 and June 30, 2021, the common stock reflected in the condensed consolidated balance sheets are reconciled in the following table:

Gross proceeds	$	80,090,410
Less:
Common stock issuance costs	$	(1,858,498)
Plus:
Accretion of carrying value to redemption value	$	1,858,498
Common stock subject to possible redemption	$	80,090,410

At June 30, 2021, the common stock subject to possible redemption reflected in the balance sheet is reconciled in the following table:

Gross proceeds	$	80,090,410
Less:
Common stock issuance costs		(1,858,498)
Plus:
Accretion of carrying value to redemption value		1,858,498
Common stock subject to possible redemption	$	80,090,410

Schedule of basic and diluted net income (loss) per common stock

	Three Months Ended
	September 30,
	2021
Basic and diluted net income (loss) per common stock
Numerator:
Allocation of net income (loss), as adjusted	$	(829,630)
Denominator:
Basic and diluted weighted average shares outstanding		10,011,301
Basic and diluted net income (loss) per common stock	$	(0.08)

			For the Period
			from
			December 18,
			2019
			(Inception)
	Year Ended		through
	June 30,		June 30,
	2021		2020
Basic and diluted net income (loss) per common stock
Numerator:
Allocation of net income (loss), as adjusted	$	(561,449)	$	(1,000)
Denominator:
Basic and diluted weighted average shares outstanding		6,734,489		1,875,000
Basic and diluted net income (loss) per common stock	$	(0.08)	$	(0.00)